Sun Pharmaceutical (SUNPHARMA.BO) Earnings Preview: EPS Seen at $10.65

Sun Pharmaceutical Industries Limited (SUNPHARMA.BO) will report Q2 2026 earnings on May 21, 2026, with analysts expecting EPS of $10.65 and revenue of $141.57B. The Mumbai-based generic pharmaceutical giant faces investor scrutiny as SUNPHARMA.BO stock trades at $1,880.50 with a PE ratio of 41.33. Ahead of the earnings announcement, we examine what Wall Street expects and key metrics that could drive the stock’s next move.

SUNPHARMA.BO Earnings Preview: EPS and Revenue Expectations

Analysts project SUNPHARMA.BO Q2 2026 earnings at $10.65 per share, representing solid growth from trailing twelve-month EPS of $45.50. Revenue expectations stand at $141.57B, reflecting steady demand across Sun Pharmaceutical’s diverse therapeutic portfolio. The company’s gross profit margin of 59.8% and operating margin of 29.8% suggest strong pricing power in generic and specialty medications.

Sun Pharmaceutical Industries Limited Stock Valuation and Key Financial Metrics

SUNPHARMA.BO stock trades at a PE ratio of 41.33, above historical averages, reflecting investor confidence in growth prospects. The company maintains a strong balance sheet with debt-to-equity of 0.067 and current ratio of 2.57. Free cash flow per share reached $9.97, while dividend yield stands at 0.88%, supporting shareholder returns amid expansion.

What to Watch in Sun Pharmaceutical Industries Limited Earnings Report

Investors should monitor revenue growth rates across key markets, particularly India and international segments. Operating margin trends matter as cost pressures could impact profitability. Management guidance on R&D spending and pipeline progress will signal confidence in future growth. Currency headwinds and generic pricing competition remain critical risks to watch closely.

SUNPHARMA.BO Stock Forecast and Analyst Outlook

Meyka AI rates SUNPHARMA.BO with a grade of B+, reflecting solid fundamentals and growth potential. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The yearly price forecast stands at $2,143.52, suggesting upside potential from current levels. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Sun Pharmaceutical Industries Limited enters Q2 2026 earnings with strong operational metrics and solid analyst expectations. The $10.65 EPS estimate reflects confidence in the company’s ability to grow earnings despite competitive pressures in generic pharmaceuticals. With a B+ grade from Meyka AI and improving financial growth metrics, investors will focus on management’s guidance and margin sustainability to determine if the stock can justify its current valuation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.